Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers.

ABSTRACT: Chimeric antigen receptor (CAR) gene-modified T cells (CAR T cells) can eradicate B cell malignancies via recognition of surface-expressed B lineage antigens. Antigen escape remains a major mechanism of relapse and is a key barrier for expanding the use of CAR T cells towards solid cancers with their more diverse surface antigen repertoires. In this review we discuss strategies by which cancers become amenable to effective CAR T cell therapy despite heterogeneous phenotypes. Pharmaceutical approaches have been reported that selectively upregulate individual target antigens on the cancer cell surface to sensitize antigen-negative subclones for recognition by CARs. In addition, advanced T cell engineering strategies now enable CAR T cells to interact with more than a single antigen simultane

SUBMITTER: Kailayangiri S 

PROVIDER: S-EPMC7281243 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature